Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

NCT ID: NCT00056446

Last Updated: 2017-03-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

855 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-01-31

Study Completion Date

2007-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and whose disease has worsened after treatment with irinotecan.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Neoplasms Colonic Neoplasms Rectal Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Oxaliplatin/5-FU/LV and PTK787/ZK 222584

Group Type EXPERIMENTAL

Vatalanib

Intervention Type DRUG

2

Oxaliplatin/5-FU/LV and placebo

Group Type PLACEBO_COMPARATOR

Vatalanib

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vatalanib

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PTK787/ZK 222584

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed adenocarcinoma of the colon or rectum in patients with metastatic disease
* One prior chemotherapy regimen with irinotecan and 5FU
* Evidence of progressive disease within 6 months after last dose of irinotecan
* WHO Performance Status of 0, 1, or 2
* Measurable tumors
* Adequate hematologic status, liver and kidney function
* Life expectancy greater than 12 weeks
* Written informed consent obtained

Exclusion Criteria

* History or presence of central nervous system disease
* Patients with a history of another primary cancer within 5 years
* Prior chemotherapy within 3 weeks before entry to study
* Major surgery within 4 weeks or minor surgery within 2 weeks before entry to study
* Investigational drugs within 4 weeks before entry to study
* Prior therapy with oxaliplatin
* Peripheral neuropathy with functional impairment
* Female patients who are pregnant or breast feeding
* Any severe or uncontrolled medical condition which could prevent participation in study
* Chronic kidney disease
* Acute or chronic liver disease
* Patients taking Coumadin
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bayer

INDUSTRY

Sponsor Role collaborator

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis/Schering AG, Germany

Role: STUDY_CHAIR

Novartis / Schering AG Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Comprehensive Cancer Institute

Huntsville, Alabama, United States

Site Status

Alaska Oncology and Hematology

Anchorage, Alaska, United States

Site Status

Arizona Clinical Research Center

Tucson, Arizona, United States

Site Status

Northeast Arkansas Clinic

Jonesboro, Arkansas, United States

Site Status

Arkansas Cancer Research Center

Little Rock, Arkansas, United States

Site Status

Little Rock Hematology & Oncology

Little Rock, Arkansas, United States

Site Status

Highlands Oncology Group

Springdale, Arkansas, United States

Site Status

Comprehensive Blood and Cancer Center

Bakersfield, California, United States

Site Status

Providence St. Joseph Medical Center

Burbank, California, United States

Site Status

Compassionate Cancer Care Medical Group, Inc.

Fountain Valley, California, United States

Site Status

California Oncology of the Central Valley

Fresno, California, United States

Site Status

Virginia K. Crosson Cancer Center

Fullerton, California, United States

Site Status

Glendale Adventist Medical Center

Glendale, California, United States

Site Status

Scripps Green Hospital

La Jolla, California, United States

Site Status

Wilshire Oncology Medical Group

La Verne, California, United States

Site Status

Pacific Shores Medical Group

Long Beach, California, United States

Site Status

USC Norris Cancer Center

Los Angeles, California, United States

Site Status

Synergy Hematology-Oncology Medical Associates

Los Angeles, California, United States

Site Status

Novartis Investigative Site

Los Angeles, California, United States

Site Status

UCLA School of Medicine

Los Angeles, California, United States

Site Status

Eddie Hong-Lung Hu, M.D.

Monterey Park, California, United States

Site Status

North Valley Hematology/Oncology Medical Group

Northridge, California, United States

Site Status

Medical Oncology Care Associates

Orange, California, United States

Site Status

Ventura County Hematology-Oncology Specialists

Oxnard, California, United States

Site Status

Sierra View District Hospital

Porterville, California, United States

Site Status

Cancer Care Associates Medical Group, Inc.

Redondo Beach, California, United States

Site Status

Santa Clara Valley Medical Center

San Jose, California, United States

Site Status

Sansum Santa Barbara Foundation Medical Clinic

Santa Barbara, California, United States

Site Status

Santa Barbara Hematology Oncology Medical Group, Inc.

Santa Barbara, California, United States

Site Status

San Diego Cancer Center Medical Group

Vista, California, United States

Site Status

Mile High Oncology

Denver, Colorado, United States

Site Status

Rocky Mountain Cancer Center

Denver, Colorado, United States

Site Status

Manchester Hematology/Oncology Assoc.

Manchester, Connecticut, United States

Site Status

Washington Oncology/Hematology Center

Washington D.C., District of Columbia, United States

Site Status

The Center for Hematology and Oncology

Boca Raton, Florida, United States

Site Status

Florida Cancer Specialists

Fort Myers, Florida, United States

Site Status

Hematology Oncology Associates

Lake Worth, Florida, United States

Site Status

University of Miami School of Medicine

Miami, Florida, United States

Site Status

Oncology/Hematology Group of South Florida

Miami, Florida, United States

Site Status

Hematology Oncology Associates of Treasure Coast

Port Saint Lucie, Florida, United States

Site Status

Florida Medical Clinic

Zephyrhills, Florida, United States

Site Status

Atlanta Cancer Care

Marietta, Georgia, United States

Site Status

Office of Research

Savannah, Georgia, United States

Site Status

Coastal Hematology & Oncology

Savannah, Georgia, United States

Site Status

Lewis Hall Singletary Oncology Center

Thomasville, Georgia, United States

Site Status

North Idaho Cancer Center

Coeur d'Alene, Idaho, United States

Site Status

University of Chicago medical Center, Hematology/Oncology

Chicago, Illinois, United States

Site Status

Oncology Hematology Associates of Central Illinois, PC

Peoria, Illinois, United States

Site Status

Northshore Cancer Research Association

Skokie, Illinois, United States

Site Status

Midwest Cancer Research Group

Skokie, Illinois, United States

Site Status

Fort Wayne Medical Oncology & Hematology, Inc.

Fort Wayne, Indiana, United States

Site Status

Munster Community Hospital

Munster, Indiana, United States

Site Status

Cotton O'Neil Oncology Clinic

Topeka, Kansas, United States

Site Status

Vijay Raghaven, M.D.

Louisville, Kentucky, United States

Site Status

Owensboro Medical Health System

Owensboro, Kentucky, United States

Site Status

Cabrini Center for Cancer Care

Alexandria, Louisiana, United States

Site Status

LSU Medical Center

New Orleans, Louisiana, United States

Site Status

Tulane University Health Sciences Center

New Orleans, Louisiana, United States

Site Status

LSU Health Sciences Center

Shreveport, Louisiana, United States

Site Status

Maine Center for Cancer Medicine & Blood Disorders

Scarborough, Maine, United States

Site Status

St. Agnes Healthcare

Baltimore, Maryland, United States

Site Status

Franklin Square Hospital Center

Baltimore, Maryland, United States

Site Status

Kaiser Permanente

Rockville, Maryland, United States

Site Status

Fallon Clinic at Worcester Medical Center

Worcester, Massachusetts, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Spectrum Health -- Cook Research Dept.

Grand Rapids, Michigan, United States

Site Status

Oncology Care Associates, PLLC

Saint Joseph, Michigan, United States

Site Status

Providence Cancer Center

Southfield, Michigan, United States

Site Status

Minnesota CGOP

Minneapolis, Minnesota, United States

Site Status

Heartland Hematology

Kansas City, Missouri, United States

Site Status

Missouri Cancer Care, PC

Saint Charles, Missouri, United States

Site Status

Saint Louis University

St Louis, Missouri, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Missouri Baptist Cancer Center

St Louis, Missouri, United States

Site Status

Arch Medical Services Incorporated

St Louis, Missouri, United States

Site Status

North Central Montana Professional Building

Great Falls, Montana, United States

Site Status

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, United States

Site Status

Nevada Cancer Center

Las Vegas, Nevada, United States

Site Status

NH Oncology-Hematology, PA

Hooksett, New Hampshire, United States

Site Status

Center for Cancer and Hematologic Disease

Cherry Hill, New Jersey, United States

Site Status

St. Barnabas Cancer Center

Livingston, New Jersey, United States

Site Status

Hematology Oncology Associates of Northern New Jersey

Morristown, New Jersey, United States

Site Status

Cooper Cancer Center

Voorhees Township, New Jersey, United States

Site Status

Hematology/Oncology Associates

Albuquerque, New Mexico, United States

Site Status

New Mexico Oncology/Hematology

Albuquerque, New Mexico, United States

Site Status

Roswell Park Cancer Institute

Buffalo, New York, United States

Site Status

Hematology/Oncology Associates of Central NY

East Syracuse, New York, United States

Site Status

Queens Medical Associates, PC

Fresh Meadows, New York, United States

Site Status

Charles R. Wood Cancer Center

Glens Falls, New York, United States

Site Status

North Shore University Hospital

Manhasset, New York, United States

Site Status

St. Vincent's Catholic Medical Centers of New York

New York, New York, United States

Site Status

Hematology-Oncology Associates of Rockland

Nyack, New York, United States

Site Status

Pluta Cancer Center

Rochester, New York, United States

Site Status

James P. Wilmot Cancer Center

Rochester, New York, United States

Site Status

Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, United States

Site Status

Carolinas Hematology/Oncology Associates

Charlotte, North Carolina, United States

Site Status

Nashat Gabrail, M.D.

Canton, Ohio, United States

Site Status

Case Western Reserve University

Cleveland, Ohio, United States

Site Status

The Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

Columbus CCOP

Columbus, Ohio, United States

Site Status

The University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States

Site Status

Oklahoma Oncology, Inc.

Tulsa, Oklahoma, United States

Site Status

Consultants in Medical Oncology & Hematology

Drexel Hill, Pennsylvania, United States

Site Status

Hematology & Oncology Associates of NE PA

Dunmore, Pennsylvania, United States

Site Status

Penn State Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

Monongahela Valley Hospital

Monongahela, Pennsylvania, United States

Site Status

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Site Status

UPMC Cancer Pavillion

Pittsburgh, Pennsylvania, United States

Site Status

Charleston Cancer Center

Charleston, South Carolina, United States

Site Status

South Carolina Oncology Associates

Columbia, South Carolina, United States

Site Status

WJB Dom VAMC

Columbia, South Carolina, United States

Site Status

Cancer Center of the Carolinas

Greenville, South Carolina, United States

Site Status

Spartanburg Regional Medical Center

Spartanburg, South Carolina, United States

Site Status

Erlanger Health System

Chattanooga, Tennessee, United States

Site Status

Clarksville Regional Hematology/Oncology

Clarksville, Tennessee, United States

Site Status

The Jones Clinic

Germantown, Tennessee, United States

Site Status

Baptist Regional Cancer Center

Knoxville, Tennessee, United States

Site Status

University of Tennessee Cancer Institute

Memphis, Tennessee, United States

Site Status

Sarah Cannon Cancer Center

Nashville, Tennessee, United States

Site Status

Meharry Medical College

Nashville, Tennessee, United States

Site Status

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States

Site Status

Vanderbilt University School of Medicine

Nashville, Tennessee, United States

Site Status

Harrington Cancer Center

Amarillo, Texas, United States

Site Status

Center for Oncology Research & Treatment

Dallas, Texas, United States

Site Status

Clinical Hematology & Oncology

Dallas, Texas, United States

Site Status

Oncology Consultants

Houston, Texas, United States

Site Status

H. Alejandro Preti, M.D., PA

Houston, Texas, United States

Site Status

M.D. Anderson Cancer Center

Houston, Texas, United States

Site Status

South Texas Oncology & Hematology

San Antonio, Texas, United States

Site Status

Scott & White Hospital

Temple, Texas, United States

Site Status

Northern Utah Cancer Associates

Ogden, Utah, United States

Site Status

Southwestern Vermont Health Care

Bennington, Vermont, United States

Site Status

Virginia Oncology Associates

Norfolk, Virginia, United States

Site Status

Cancer Treatment Centers of America in Hampton Roads

Portsmouth, Virginia, United States

Site Status

Western Washington Clinic

Everett, Washington, United States

Site Status

Cascade Cancer Center

Kirkland, Washington, United States

Site Status

Rainier Oncology

Puyallup, Washington, United States

Site Status

Virginia Mason Medical Center

Seattle, Washington, United States

Site Status

Swedish Cancer Institute

Seattle, Washington, United States

Site Status

West Virginia University Health Sciences Center

Morgantown, West Virginia, United States

Site Status

Waukesha Memorial Hospital

Waukesha, Wisconsin, United States

Site Status

Kettle Morain Oncology

West Bend, Wisconsin, United States

Site Status

Novartis Investigative Site

Frankston, , Australia

Site Status

Novartis Investigative Site

Woodville South, , Australia

Site Status

Novartis Investigative Site

Sankt Veit an der Glan, , Austria

Site Status

Novartis Investigative Site

Antwerp, , Belgium

Site Status

Novartis Investigative Site

Brasschaat, , Belgium

Site Status

Novartis Investigative Site

Brussels, , Belgium

Site Status

Novartis Investigative Site

Leuven, , Belgium

Site Status

Novartis Investigative Site

Liège, , Belgium

Site Status

Novartis Investigative Site

Wilrijk, , Belgium

Site Status

Novartis Investigative Site

Porto Alegre RS, , Brazil

Site Status

Novartis Investigative Site

Salvador - Ba, , Brazil

Site Status

Novartis Investigative Site

Salvador, Bahia, , Brazil

Site Status

Novartis Investigative Site

São Paulo, , Brazil

Site Status

Novartis Investigative Site

São Paulo, , Brazil

Site Status

Novartis Investigative Site

São Paulo, , Brazil

Site Status

Novartis Investigative Site

Calgary, Alberta, Canada

Site Status

Novartis Investigative Site

Penticton, British Columbia, Canada

Site Status

Novartis Investigative Site

Winnepeg, Manitoba, Canada

Site Status

Novartis Investigative Site

Sydney, Nova Scotia, Canada

Site Status

Novartis Investigative Site

Barrie, Ontario, Canada

Site Status

Novartis Investigative Site

Brampton, Ontario, Canada

Site Status

Novartis Investigative Site

Greater Sudbury, Ontario, Canada

Site Status

Novartis Investigative Site

Hamilton, Ontario, Canada

Site Status

Novartis Investigative Site

Ottawa, Ontario, Canada

Site Status

Novartis Investigative Site

Sainte-Foy, Ontario, Canada

Site Status

Novartis Investigative Site

St. Catharines, Ontario, Canada

Site Status

Novartis Investigative Site

Thunder Bay, Ontario, Canada

Site Status

Toronto, Ontario, Canada

Site Status

Novartis Investigative Site

Toronto, Ontario, Canada

Site Status

Novartis Investigative Site

Toronto, Ontario, Canada

Site Status

Novartis Investigative Site

Toronto, Ontario, Canada

Site Status

Novartis Investigative Site

Windsor, Ontario, Canada

Site Status

Novartis Investigative Site

Greenfield Park, Quebec, Canada

Site Status

Novartis Investigative Site

Montreal, Quebec, Canada

Site Status

Novartis Investigative Site

Montreal, Quebec, Canada

Site Status

Novartis Investigative Site

Saskatoon, Saskatchewan, Canada

Site Status

Novartis Investigative Site

Avignon, , France

Site Status

Novartis Investigative Site

Boulogne, , France

Site Status

Novartis Investigative Site

Lille, , France

Site Status

Novartis Investigative Site

Marseille, , France

Site Status

Novartis Investigative Site

Montpellier, , France

Site Status

Novartis Investigative Site

Nice, , France

Site Status

Novartis Investigative Site

Rennes, , France

Site Status

Novartis Investigative Site

Saint-Herblain, , France

Site Status

Novartis Investigative Site

Strasbourg, , France

Site Status

Novartis Investigative Site

Toulouse, , France

Site Status

Novartis Investigative Site

Augsburg, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Bielefeld, , Germany

Site Status

Novartis Investigative Site

Braunschweig, , Germany

Site Status

Novartis Investigative Site

Cologne, , Germany

Site Status

Novartis Investigative Site

Dessau, , Germany

Site Status

Novartis Investigative Site

Dresden, , Germany

Site Status

Novartis Investigative Site

Essen, , Germany

Site Status

Novartis Investigative Site

Essen, , Germany

Site Status

Novartis Investigative Site

Frankfurt, , Germany

Site Status

Novartis Investigative Site

Hamburg, , Germany

Site Status

Novartis Investigative Site

Hanover, , Germany

Site Status

Novartis Investigative Site

Magdeburg, , Germany

Site Status

Novartis Investigative Site

München, , Germany

Site Status

Novartis Investigative Site

Neumünster, , Germany

Site Status

Novartis Investigative Site

Trier, , Germany

Site Status

Novartis Investigative Site

Ulm, , Germany

Site Status

Novartis Investigative Site

Wiesbaden, , Germany

Site Status

Novartis Investigative Site

Chai Wan, , Hong Kong

Site Status

Novartis Investigative Site

Ancona, , Italy

Site Status

Novartis Investigative Site

Bergamo, , Italy

Site Status

Novartis Investigative Site

Brescia, , Italy

Site Status

Novartis Investigative Site

Cremona, , Italy

Site Status

Novartis Investigative Site

Genova, , Italy

Site Status

Novartis Investigative Site

Livorno, , Italy

Site Status

Novartis Investigative Site

Milan, , Italy

Site Status

Novartis Investigative Site

Milan, , Italy

Site Status

Novartis Investigative Site

Reggio Emilia, , Italy

Site Status

Novartis Investigative Site

Roma, , Italy

Site Status

Novartis Investigative Site

Roma, , Italy

Site Status

Novartis Investigative Site

Rozzano, , Italy

Site Status

Novartis Investigative Site

Auckland, , New Zealand

Site Status

Novartis Investigative Site

Christchurch, , New Zealand

Site Status

Novartis Investigative Site

Wellington, , New Zealand

Site Status

Novartis Investigative Site

Coimbra, , Portugal

Site Status

Novartis Investigative Site

Lisbon, , Portugal

Site Status

Novartis Investigative Site

Bratislava, , Slovakia

Site Status

Novartis Investigative Site

Córdoba, , Spain

Site Status

Novartis Investigative Site

Elche, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Málaga, , Spain

Site Status

Novartis Investigative Site

Zaragoza, , Spain

Site Status

Novartis Investigative Site

Gothenburg, , Sweden

Site Status

Novartis Investigative Site

Stockholm, , Sweden

Site Status

Novartis Investigative Site

Bern, , Switzerland

Site Status

Novartis Investigative Site

Thun, , Switzerland

Site Status

Novartis Investigative Site

Changhua, , Taiwan

Site Status

Novartis Investigative Site

Kaohsiung City, , Taiwan

Site Status

Novartis Investigative Site

Keelung, , Taiwan

Site Status

Novartis Investigative Site

Taichung, , Taiwan

Site Status

Novartis Investigative Site

Tainan City, , Taiwan

Site Status

Novartis Investigative Site

Taipei, , Taiwan

Site Status

Novartis Investigative Site

Taoyuan District, , Taiwan

Site Status

Novartis Investigative Site

Belfast, , United Kingdom

Site Status

Novartis Investigative Site

Birmingham, , United Kingdom

Site Status

Novartis Investigative Site

Cardiff, , United Kingdom

Site Status

Novartis Investigative Site

London, , United Kingdom

Site Status

Novartis Investigative Site

Manchester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Brazil Canada France Germany Hong Kong Italy New Zealand Portugal Slovakia Spain Sweden Switzerland Taiwan United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Van Cutsem E, Bajetta E, Valle J, Kohne CH, Hecht JR, Moore M, Germond C, Berg W, Chen BL, Jalava T, Lebwohl D, Meinhardt G, Laurent D, Lin E. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol. 2011 May 20;29(15):2004-10. doi: 10.1200/JCO.2010.29.5436. Epub 2011 Apr 4.

Reference Type RESULT
PMID: 21464401 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CPTK787 0133/304946

Identifier Type: -

Identifier Source: org_study_id

NCT00068679

Identifier Type: -

Identifier Source: nct_alias

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Colorectal Cancer RECHALLENGE
NCT00988897 WITHDRAWN PHASE2